Jupiter Topco LLC Buys Shares of 2,164,836 Stryker Corporation $SYK

Jupiter Topco LLC purchased a new position in Stryker Corporation (NYSE:SYK) in the 2nd quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The institutional investor purchased 2,164,836 shares of the medical technology company’s stock, valued at approximately $681,581,000.

Several other institutional investors have also modified their holdings of SYK. VanderPol Investments L.L.C. increased its stake in Stryker by 1.4% during the 4th quarter. VanderPol Investments L.L.C. now owns 2,084 shares of the medical technology company’s stock worth $732,000 after purchasing an additional 28 shares in the last quarter. KCM Investment Advisors LLC lifted its stake in Stryker by 1.5% in the fourth quarter. KCM Investment Advisors LLC now owns 1,857 shares of the medical technology company’s stock valued at $653,000 after buying an additional 28 shares in the last quarter. Rossby Financial LCC boosted its holdings in shares of Stryker by 6.6% in the fourth quarter. Rossby Financial LCC now owns 451 shares of the medical technology company’s stock valued at $159,000 after buying an additional 28 shares during the period. Tcfg Wealth Management LLC increased its position in shares of Stryker by 2.7% during the third quarter. Tcfg Wealth Management LLC now owns 1,091 shares of the medical technology company’s stock worth $403,000 after acquiring an additional 29 shares in the last quarter. Finally, ICW Investment Advisors LLC increased its position in shares of Stryker by 0.6% during the fourth quarter. ICW Investment Advisors LLC now owns 5,096 shares of the medical technology company’s stock worth $1,791,000 after acquiring an additional 30 shares in the last quarter. Institutional investors own 77.09% of the company’s stock.

Stryker Stock Performance

Shares of NYSE SYK opened at $331.06 on Wednesday. The company has a debt-to-equity ratio of 0.59, a quick ratio of 1.33 and a current ratio of 2.16. The stock has a 50 day moving average price of $327.80 and a 200 day moving average price of $331.95. The stock has a market capitalization of $126.98 billion, a PE ratio of 34.31, a price-to-earnings-growth ratio of 2.09 and a beta of 0.76. Stryker Corporation has a 52 week low of $281.00 and a 52 week high of $396.86.

Stryker (NYSE:SYK) last posted its quarterly earnings results on Thursday, July 30th. The medical technology company reported $3.69 earnings per share for the quarter, topping the consensus estimate of $3.49 by $0.20. Stryker had a return on equity of 23.63% and a net margin of 14.43%.The firm had revenue of $6.59 billion for the quarter, compared to analyst estimates of $6.58 billion. During the same quarter in the previous year, the firm earned $3.13 EPS. The business’s quarterly revenue was up 9.4% on a year-over-year basis. Stryker has set its FY 2026 guidance at 14.950-15.100 EPS. Analysts predict that Stryker Corporation will post 15.02 earnings per share for the current fiscal year.

Stryker Announces Dividend

The company also recently declared a quarterly dividend, which will be paid on Friday, October 30th. Shareholders of record on Wednesday, September 30th will be given a dividend of $0.88 per share. This represents a $3.52 annualized dividend and a yield of 1.1%. The ex-dividend date of this dividend is Wednesday, September 30th. Stryker’s dividend payout ratio is 36.48%.

Wall Street Analysts Forecast Growth

Several research firms recently commented on SYK. Piper Sandler cut their price objective on shares of Stryker from $420.00 to $390.00 and set an “overweight” rating on the stock in a research report on Friday, July 31st. UBS Group initiated coverage on Stryker in a research note on Tuesday, July 28th. They issued a “buy” rating and a $400.00 price target on the stock. BMO Capital Markets assumed coverage on Stryker in a report on Wednesday, July 8th. They issued an “outperform” rating and a $369.00 price target on the stock. Truist Financial increased their price objective on Stryker from $330.00 to $340.00 and gave the stock a “hold” rating in a report on Friday, July 31st. Finally, Canaccord Genuity Group dropped their target price on Stryker from $435.00 to $400.00 and set a “buy” rating on the stock in a research report on Friday, May 1st. One equities research analyst has rated the stock with a Strong Buy rating, seventeen have issued a Buy rating and six have issued a Hold rating to the company. According to MarketBeat.com, Stryker presently has a consensus rating of “Moderate Buy” and an average target price of $386.28.

Insiders Place Their Bets

In other Stryker news, insider Debra King sold 826 shares of the stock in a transaction on Tuesday, August 18th. The shares were sold at an average price of $336.30, for a total value of $277,783.80. Following the completion of the sale, the insider owned 6,210 shares in the company, valued at $2,088,423. This trade represents a 11.74% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is available through this link. Also, VP Robert S. Fletcher sold 4,544 shares of Stryker stock in a transaction dated Thursday, May 28th. The shares were sold at an average price of $306.87, for a total transaction of $1,394,417.28. Following the completion of the transaction, the vice president directly owned 10,582 shares of the company’s stock, valued at approximately $3,247,298.34. This trade represents a 30.04% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Over the last three months, insiders have sold 355,370 shares of company stock valued at $119,447,201. 4.60% of the stock is currently owned by corporate insiders.

Stryker Profile

Stryker Corporation is a global medical technology company that designs, manufactures and markets a broad range of products and services for use in hospitals, surgeons’ offices and other healthcare facilities. Its primary business activities span orthopedics (including joint replacement implants, trauma and extremities products), surgical equipment and operating room technologies (such as visualization, navigation and powered instruments), neurotechnology and spine solutions, and patient-handling and emergency medical equipment.